CureVac abandons the development of the first-generation COVID-19 vaccine

Article source: Medical Rubik's Cube Info

Author: Shi Bei

On October 12, the German company CureVac announced that the development of the COVID-19 vaccine will focus on the development of the second-generation mRNA candidate vaccine in cooperation with GSK, and its first-generation COVID-19 candidate vaccine CVnCoV will be obtained from the European Medicines Agency ( EMA) withdrawn in the current approval process

Based on a recent communication with EMA, CureVac estimates that the earliest potential approval date for CVnCoV may be in the second quarter of 2022

CureVac is one of the earliest companies that announced that they would develop an mRNA new crown vaccine

In June 2021, CureVac announced the second interim data of the key phase II/III clinical trial HERALD (NCT04652102) of its mRNA vaccine CVnCoV to prevent new coronavirus infection

After the news came out, CureVac's stock price fell sharply

On September 28, Sanofi announced that its first COVID-19 mRNA vaccine (R&D code MRT5500) Phase I/II study had positive mid-term results

Then Sanofi issued a news, saying that considering the current public health needs and the global supply of mRNA COVID-19 vaccine, it decided not to advance the phase III clinical research of the new crown mRNA vaccine, but to focus on the COVID-19 recombination developed in cooperation with GSK Vaccine

CureVac said that it is accelerating the previous mRNA cooperation with GSK, by investing more resources to accelerate the development of the second-generation mRNA vaccine project